Patient info Open main menu

Hydrex Surgical Scrub Chlorhexidine 4% w/v Skin Cleanser – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine strength:
4% w/v
Contains active substance:

Summary of Product Characteristics (SmPC) - Hydrex Surgical Scrub Chlorhexidine 4% w/v Skin Cleanser

1 NAME OF THE MEDICINAL PRODUCT

Hydrex Surgical Scrub Chlorhexidine 4% w/v Skin Cleanser

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Chlorhexidine Gluconate 4% w/v.

3 PHARMACEUTICAL FORM

Solution.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For use as an antiseptic hand wash, a pre-operative hand scrub and a pre-operative skin preparation to surgery.

4.2 Posology and method of administration

Antiseptic hand wash - wet the hands and forearms, apply 5 ml of skin cleanser and wash for one minute. Rinse thoroughly and dry.

Pre-operative Surgical Scrub - wet hands and forearms, apply 5 ml of skin cleanser and wash for one minute, cleaning the finger nails with a brush. Rinse and repeat the procedure using a further 5 ml of skin cleanser and wash for 2 minutes. Rinse thoroughly and dry.

Pre-operative Skin Preparation - the patient should wash his whole body with 25 ml of the cleanser on at least two occasions, usually the day before and on the day of the operation.

4.3 Contraindications

Avoid contact with eyes, middle ear, brain and meninges.

Known hypersensitivity to the product or any of its components, especially in those with a history of possible chlorhexidine-related allergic reactions (see sections 4.4 and 4.8).

4.4 Special warnings and precautions for use

For external use only.

Keep out of the reach and sight of children.

Do not use in body cavities.

The use of chlorhexidine solutions, both alcohol based and aqueous, for skin antisepsis prior to invasive procedures has been associated with chemical burns in neonates. Based on available case reports and the published literature, this risk appears to be higher in preterm infants, especially those born before 32 weeks of gestation and within the first 2 weeks of life.

Remove any soaked materials, drapes or gowns before proceeding with the intervention. Do not use excessive quantities and do not allow the solution to pool in skin folds or under the patient or drip on sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to Hydrex Surgical Scrub, care must be taken to ensure no excess product is present prior to application of the dressing.

Hydrex Surgical Scrub must not come into contact with the eye. Serious cases of persistent corneal injury, potentially requiring corneal transplant, were reported following accidental ocular exposure to chlorhexidine containing medicinal products despite taking eye protective measure due to migration of solution beyond the intended surgical preparation area. Extreme care must be taken during application to ensure that Hydrex Surgical Scrub does not migrate beyond its intended application site into the eyes. Particular care should be taken in anaesthetised patients, who are unable to immediately report ocular exposure. If Hydrex Surgical Scrub comes into contact with the eyes, wash out promptly and thoroughly with water. An ophthalmologist’s advice should be sought.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

No special precautions need to be taken when used in pregnancy and lactation.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

Immune disorders

  • Frequency not known
  • Hypersensitivity including anaphylactic shock (see sections 4.3 and 4.4) to chlorhexidine gluconate or amine oxide, particularly on repeated use.

Skin disorders

Frequency not known:

  • Allergic skin reactions such as dermatitis, pruritus, erythema, eczema, rash, urticarial, skin irritation, and blisters.
  • Chemical burns in neonates.

Eye Disorder

Frequency not known:

  • Corneal erosion, epithelium defect/corneal injury, significant permanent visual impairment*

*Cases of severe corneal erosion and permanent significant visual impairment due to inadvertent ocular exposure have been reported post-marketing, leading to some patients requiring corneal transplant (see section 4.4).

Reporting of suspected adverse reactions

System Organ

Class

Very Common ( 1/10)

Common ( 1/100 <

1/10)

Uncommon ( 1/1,000 <

1/100)

Rare

( 1/10,000 < 1/1,000)

Very Rare (< 1/10,000)Not known (cannot be estimated from available data)
Immune System Disorders

Hypersensitivity

Anaphylactic shock

Skin and Subcutaneous

Tissue

Disorders

Allergic skin reactions

Chemical burns neonates

Eye DisorderCorneal erosion, epithelium defect/corneal injury, significant permanent visual impairment*

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Chlorhexidine is poorly absorbed. If swallowed treat with gastric lavage. Employ supportive measures as appropriate.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Chlorhexidine is a bisbiguanide disinfectant which is active against a wide range of Gram-positive and Gram-negative vegetative bacteria. It is also active against some viruses and fungi. It is most active at neutral or slightly acid pH.

5.2 Pharmacokinetic properties

Percutaneous absorption of chlorhexidine gluconate is negligible and leads to clinically insignificant plasma concentrations.

5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, carcinogenic potential and toxicity to reproduction.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Ponceau 4R

Dialkylamine Oxide

Glycerine

Industrial Methylated Spirit

Hydroxyethyl Cellulose

Purified Water

Perfume

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

Hydrex Surgical Scrub is packaged in:

100ml HDPE container with a Black Polypropylene Screw Cap with EPE Wad 250 ml HDPE container with a White Polypropylene Flip Top Cap 500 ml HDPE container with a Black Polypropylene Screw Cap with EPE Wad 2000 ml HDPE container with a Black Polypropylene Screw Cap with EPE Wad 5000 ml HDPE container with a Black Polypropylene Screw Cap with EPE Wad

6.6 Special precautions for disposal

Not applicable.

7 MARKETING AUTHORISATION HOLDER

Ecolab Ltd, Unit 1, Wernddu Court, Caerphilly, CF83 3SG, UK.

8 MARKETING AUTHORISATION NUMBER(S)

PL 04509/0020

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

01/03/2003

10 DATE OF REVISION OF THE TEXT

17/09/2024

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 04509/0020

Last revision stated in the text: 17 September 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Hydrex Surgical Scrub Chlorhexidine 4% w/v Skin Cleanser

Active substance Chlorhexidine
Strength 4% w/v
Excipients Ponceau 4R, Dialkylamine Oxide, Glycerine, Industrial Methylated Spirit, Hydroxyethyl Cellulose, Purified Water, Perfume
Shelf life 3 years.
Storage Store below 25°C.
Marketing authorisation PL 04509/0020 (first authorised 1 March 2003)
Marketing authorisation holder Ecolab Ltd, Unit 1, Wernddu Court, Caerphilly, CF83 3SG, UK.

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.